Pharming Group (PHAR) Stock Forecast, Price Target & Predictions
PHAR Stock Forecast
Pharming Group stock forecast is as follows: an average price target of $14.00 (represents a 53.85% upside from PHAR’s last price of $9.10) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PHAR Price Target
The average price target for Pharming Group (PHAR) is $14.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 53.85% upside from PHAR's last price of $9.10.
PHAR Analyst Ratings
According to 3 Wall Street analysts, Pharming Group's rating consensus is 'Buy'. The analyst rating breakdown for PHAR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pharming Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2024 | Lucy Codrington | Jefferies | $14.00 | $7.72 | 81.35% | 53.85% |
The latest Pharming Group stock forecast, released on Dec 09, 2024 by Lucy Codrington from Jefferies, set a price target of $14.00, which represents a 81.35% increase from the stock price at the time of the forecast ($7.72), and a 53.85% increase from PHAR last price ($9.10).
Pharming Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $14.00 | $14.00 | $14.00 |
| Last Closing Price | $9.10 | $9.10 | $9.10 |
| Upside/Downside | 53.85% | 53.85% | 53.85% |
In the current month, the average price target of Pharming Group stock is $14.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 53.85% increase as opposed to Pharming Group's last price of $9.10. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 09, 2024 | Jefferies | Buy | Initialise | |
| Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 28, 2023 | Oppenheimer | Outperform | Outperform | Hold |
Pharming Group's last stock rating was published by Jefferies on Dec 09, 2024. The company Initialise its PHAR rating from "null" to "Buy".
Pharming Group Financial Forecast
Pharming Group Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $42.54M | $54.62M | $54.24M | $50.15M | $46.62M | $45.75M | $44.63M | $41.26M | $36.04M | $50.98M | $46.12M | $39.30M | $49.29M | $45.66M | $45.42M | $42.71M | $35.22M |
| Avg Forecast | $91.40M | $84.00M | $81.00M | $64.00M | $81.25M | $76.93M | $71.94M | $68.42M | $71.83M | $61.67M | $53.23M | $50.34M | $60.25M | $53.50M | $51.99M | $47.65M | $57.58M | $59.59M | $66.93M | $61.29M | $59.49M | $55.09M | $55.92M | $52.80M | $51.73M | $48.54M | $47.07M | $41.49M |
| High Forecast | $91.67M | $84.25M | $81.24M | $64.19M | $83.60M | $80.32M | $74.39M | $70.80M | $72.74M | $63.27M | $53.39M | $50.49M | $60.43M | $53.50M | $51.99M | $47.65M | $57.58M | $59.59M | $66.93M | $61.29M | $59.49M | $55.09M | $55.92M | $52.80M | $51.73M | $48.54M | $47.07M | $41.49M |
| Low Forecast | $90.71M | $83.37M | $80.39M | $63.52M | $79.37M | $73.54M | $69.48M | $66.05M | $70.91M | $60.07M | $52.83M | $49.96M | $59.80M | $53.50M | $51.99M | $47.65M | $57.58M | $59.59M | $66.93M | $61.29M | $59.49M | $55.09M | $55.92M | $52.80M | $51.73M | $48.54M | $47.07M | $41.49M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 0.91% | 1.01% | 0.96% | 0.98% | 0.79% | 0.75% | 0.62% | 0.59% | 0.86% | 0.84% | 0.70% | 0.93% | 0.88% | 0.94% | 0.91% | 0.85% |
Pharming Group's average Quarter revenue forecast for Jun 23 based on 1 analysts is $53.23M, with a low forecast of $52.83M, and a high forecast of $53.39M. PHAR's average Quarter revenue forecast represents a 25.13% increase compared to the company's last Quarter revenue of $42.54M (Mar 23).
Pharming Group EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-11.57M | $-11.84M | $12.48M | $22.98M | $7.80M | $13.95M | $4.47M | $9.19M | $13.61M | $-6.08M | $25.35M | $10.14M | $21.66M | $14.74M | $21.02M | $10.38M | $11.07M |
| Avg Forecast | $22.69M | $20.85M | $20.10M | $15.88M | $20.17M | $19.09M | $17.85M | $16.98M | $17.83M | $15.31M | $13.21M | $12.49M | $14.95M | $12.77M | $12.41M | $11.38M | $13.75M | $14.23M | $27.88M | $14.63M | $14.21M | $13.15M | $13.35M | $12.61M | $12.35M | $11.59M | $11.24M | $9.91M |
| High Forecast | $22.75M | $20.91M | $20.16M | $15.93M | $20.75M | $19.94M | $18.46M | $17.57M | $18.06M | $15.70M | $13.25M | $12.53M | $15.00M | $12.77M | $12.41M | $11.38M | $13.75M | $14.23M | $33.46M | $14.63M | $14.21M | $13.15M | $13.35M | $12.61M | $12.35M | $11.59M | $11.24M | $9.91M |
| Low Forecast | $22.51M | $20.69M | $19.95M | $15.77M | $19.70M | $18.25M | $17.25M | $16.39M | $17.60M | $14.91M | $13.11M | $12.40M | $14.84M | $12.77M | $12.41M | $11.38M | $13.75M | $14.23M | $22.30M | $14.63M | $14.21M | $13.15M | $13.35M | $12.61M | $12.35M | $11.59M | $11.24M | $9.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -0.93% | -0.79% | 0.98% | 1.85% | 0.69% | 1.01% | 0.31% | 0.33% | 0.93% | -0.43% | 1.93% | 0.76% | 1.72% | 1.19% | 1.81% | 0.92% | 1.12% |
1 analysts predict PHAR's average Quarter EBITDA for Dec 22 to be $14.95M, with a high of $15.00M and a low of $14.84M. This is 19.82% upper than Pharming Group's previous annual EBITDA (Sep 22) of $12.48M.
Pharming Group Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-12.21M | $-14.63M | $9.10M | $15.74M | $3.46M | $1.86M | $-272.00K | $4.85M | $7.05M | $7.44M | $7.45M | $9.72M | $8.43M | $12.14M | $10.46M | $6.86M | $6.74M |
| Avg Forecast | $472.42K | $-472.42K | $-472.42K | $-472.42K | $897.60K | $-115.71K | $-96.35K | $336.75K | $211.41K | $-6.37M | $-4.58M | $-3.09M | $2.64M | $1.74M | $5.83M | $-3.68M | $209.40K | $2.42M | $14.71M | $7.98M | $4.67M | $10.90M | $8.47M | $11.74M | $9.12M | $7.63M | $6.99M | $6.10M |
| High Forecast | $474.27K | $-467.79K | $-467.79K | $-467.79K | $1.06M | $-114.58K | $-95.40K | $338.06K | $212.24K | $-6.31M | $-4.54M | $-3.06M | $2.65M | $1.74M | $5.83M | $-3.68M | $209.40K | $2.42M | $17.65M | $7.98M | $4.67M | $10.90M | $8.47M | $11.74M | $9.12M | $7.63M | $6.99M | $6.10M |
| Low Forecast | $467.79K | $-474.27K | $-474.27K | $-474.27K | $739.20K | $-116.17K | $-96.72K | $333.45K | $209.34K | $-6.40M | $-4.60M | $-3.10M | $2.62M | $1.74M | $5.83M | $-3.68M | $209.40K | $2.42M | $11.77M | $7.98M | $4.67M | $10.90M | $8.47M | $11.74M | $9.12M | $7.63M | $6.99M | $6.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 3.95% | -5.54% | 5.24% | 2.70% | -0.94% | 8.89% | -0.11% | 0.33% | 0.88% | 1.59% | 0.68% | 1.15% | 0.72% | 1.33% | 1.37% | 0.98% | 1.10% |
Pharming Group's average Quarter net income forecast for Dec 22 is $2.64M, with a range of $2.62M to $2.65M. PHAR's average Quarter net income forecast represents a -70.97% decrease compared to the company's last Quarter net income of $9.10M (Sep 22).
Pharming Group SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $37.09M | $46.55M | $32.40M | $27.95M | $24.93M | $25.89M | $19.14M | $18.07M | $18.20M | $11.10M | $14.88M | $14.23M | $16.68M | $17.86M | $13.34M | $15.08M | $12.54M |
| Avg Forecast | $39.06M | $35.90M | $34.62M | $27.35M | $34.73M | $32.88M | $30.74M | $29.24M | $30.70M | $26.36M | $22.75M | $21.52M | $25.75M | $22.87M | $22.22M | $20.37M | $24.61M | $25.47M | $54.83M | $26.19M | $25.43M | $23.55M | $23.90M | $22.57M | $22.11M | $20.75M | $20.12M | $17.73M |
| High Forecast | $39.18M | $36.01M | $34.72M | $27.44M | $35.73M | $34.33M | $31.79M | $30.26M | $31.09M | $27.04M | $22.82M | $21.58M | $25.83M | $22.87M | $22.22M | $20.37M | $24.61M | $25.47M | $65.80M | $26.19M | $25.43M | $23.55M | $23.90M | $22.57M | $22.11M | $20.75M | $20.12M | $17.73M |
| Low Forecast | $38.77M | $35.63M | $34.36M | $27.15M | $33.92M | $31.43M | $29.70M | $28.23M | $30.30M | $25.67M | $22.58M | $21.35M | $25.56M | $22.87M | $22.22M | $20.37M | $24.61M | $25.47M | $43.86M | $26.19M | $25.43M | $23.55M | $23.90M | $22.57M | $22.11M | $20.75M | $20.12M | $17.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.72% | 1.81% | 1.42% | 1.26% | 1.22% | 1.05% | 0.75% | 0.33% | 0.69% | 0.44% | 0.63% | 0.60% | 0.74% | 0.81% | 0.64% | 0.75% | 0.71% |
Pharming Group's average Quarter SG&A projection for Jun 23 is $22.75M, based on 1 Wall Street analysts, with a range of $22.58M to $22.82M. The forecast indicates a -38.66% fall compared to PHAR last annual SG&A of $37.09M (Mar 23).
Pharming Group EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.19 | $-0.21 | $0.13 | $0.23 | $0.05 | $0.03 | $-0.00 | $0.08 | $0.11 | $0.11 | $0.12 | $0.15 | $0.13 | $0.19 | $0.16 | $0.11 | $0.11 |
| Avg Forecast | $0.01 | $-0.01 | $-0.01 | $-0.01 | $0.02 | $-0.00 | $-0.00 | $0.01 | - | $-0.12 | $-0.09 | $-0.06 | $0.05 | $0.03 | $0.09 | $-0.05 | - | $0.04 | $0.14 | $0.12 | $0.07 | $0.16 | $0.12 | $0.17 | $0.13 | $0.11 | $0.10 | $0.09 |
| High Forecast | $0.01 | $-0.01 | $-0.01 | $-0.01 | $0.02 | $-0.00 | $-0.00 | $0.01 | - | $-0.12 | $-0.09 | $-0.06 | $0.05 | $0.03 | $0.09 | $-0.05 | - | $0.04 | $0.14 | $0.12 | $0.07 | $0.16 | $0.12 | $0.17 | $0.13 | $0.11 | $0.10 | $0.09 |
| Low Forecast | $0.01 | $-0.01 | $-0.01 | $-0.01 | $0.01 | $-0.00 | $-0.00 | $0.01 | - | $-0.12 | $-0.09 | $-0.06 | $0.05 | $0.03 | $0.09 | $-0.05 | - | $0.04 | $0.14 | $0.12 | $0.07 | $0.16 | $0.12 | $0.17 | $0.13 | $0.11 | $0.10 | $0.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 3.18% | -4.11% | 5.08% | 2.67% | -0.92% | 9.39% | -0.12% | 0.54% | 0.93% | 1.60% | 0.72% | 1.20% | 0.75% | 1.39% | 1.43% | 1.09% | 1.22% |
According to 1 Wall Street analysts, Pharming Group's projected average Quarter EPS for Dec 22 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -60.68% decrease compared to PHAR previous annual EPS of $0.13 (Sep 22).
Pharming Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals | $0.70 | $12.00 | 1614.29% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| PRTC | PureTech Health | $21.80 | $57.00 | 161.47% | Buy |
| FENC | Fennec Pharmaceuticals | $6.07 | $15.75 | 159.47% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHAR | Pharming Group | $8.80 | $14.00 | 59.09% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| JANX | Janux Therapeutics | $59.61 | $70.25 | 17.85% | Buy |